Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Zentek Ltd. (V:ZEN)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for ZEN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 25, 2024 08:00 ET
Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA
GUELPH, ON / ACCESSWIRE / March 25, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera") has completed testing demonstrating that its C19HBA SARS-CoV-2 universal aptamer built on the proprietary high-binding affinity aptamer platform has shown a promising safety and toxicity profile in preclinical testing. This is a critical step in the path towards the development of a human therapeutic.
Read full article
Jan 30, 2024 08:13 ET
Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA
GUELPH, ON / ACCESSWIRE / January 30, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN) announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera")has completed testing of its C19HBA aptamer as a potential therapeutic. The SARS-CoV-2 universal aptamer built on the proprietary high-binding affinity aptamer platform successfully outperformed a leading monoclonal antibody ("LMA") in preclinical testing demonstrating potential as a therapeutic for SARS-CoV-2.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.84
--
--
Price to Sales - TTM
4,799.50
2.67
3.46
Price to Book - most recent quarter
7.18
2.57
2.02
Price to Cash Flow per share - TTM
--
6.21
9.70
Price to Free Cash Flow per share - TTM
--
20.97
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 20241,465,851-12,739
Feb 29, 20241,478,590-2,795
Feb 15, 20241,481,385-14,343
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Company's developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.

See business summary

 

Twitter

Search (past week) for $ZEN.CA ZEN.V

  • No tweets found